Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Aurobindo Pharma has informed that a Meeting of the Board of Directors of the Company will be held on Thursday, February 6, 2025, to consider and approve, the Standalone & Consolidated Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2024. Further to its letter dated December 25, 2024, informing the closure of Trading Window of the Company from January 1, 2025, until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2024, it has informed that the Trading Window will remain closed up to February 8, 2025, and shall be re-opened on February 9, 2025.
The above information is a part of company’s filings submitted to BSE.
